Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.

Neoadjuvant niraparib achieved an 80% R0 resection rate in HRD-positive advanced ovarian cancer patients initially unsuitable for primary debulking surgery.

• Why it matters: This study addresses the need for effective, chemotherapy-free neoadjuvant options for patients with HRD-positive ovarian cancer who are unlikely to benefit from standard surgery, filling a gap in treatment strategies.
• What they did: Researchers conducted a single-arm, phase 2 trial involving 67 Chinese women with FIGO stage III-IV HRD-positive high-grade serous or endometrioid ovarian cancer, administering two cycles of oral niraparib and assessing objective response and R0 resection rates.
• The result: The trial found a 63% objective response rate among response-evaluable patients and an 80% R0 resection rate among operated patients, indicating anti-tumour activity and surgical success, though further validation is needed.